Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

- PMLiVE

First blood to Roche in Hemlibra patent fight with Shire

The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court

Roche Basel Switzerland

Another Tecentriq win for Roche as Avastin combo boosts survival

The Swiss pharma group reported a 38% improvement in PFS in NSCLC patients

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

Digital shakeout

Recent announcements by Nokia, Roche and others point to where digital health is heading

Roche Basel Switzerland

Roche wins European approval for bleeding disorder treatment Hemlibra

It's the first new medicine in over 20 years to treat patients with inhibitors

Eli Lilly HQ

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

Studies show the drug improves PFS when used with an aromatase inhibitor

Eli Lilly HQ

Lilly drops Hanmi-partnered arthritis drug

Concludes that its BTK inhibitor is likely to be clinically ineffective

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links